Belsomra, Merck’s new sleeping pill, is now the hottest topic on this blog. Insomnia sufferers who write in with comments are wondering about dosage, effectiveness, side effects, and how it compares with other sleeping pills.
Reviews of Belsomra, or suvorexant, have been lukewarm so far. Since I haven’t tried it myself, I can’t weigh in based on personal experience. But my search for information turned up more than I shared in my blog last August. Here’s a bit of context and more details.
Roll over, Ambien! After much debate, the FDA has finally approved Merck’s new drug for insomnia. Expect to see Belsomra (a.k.a. suvorexant) on the market early next year.
So what can we hope for from this new sleeping pill and how does it differ from hypnotics available now?
My hope springs eternal when it comes to the possibility of a better sleeping pill. Suvorexant, Merck’s new insomnia drug, is currently under review at the FDA, and I’m wondering whether this will be it.
Suvorexant is a different from sleeping pills like Ambien (a.k.a. zolpidem) and Lunesta. These older pills work by enhancing the activity of GABA, the main neurotransmitter that shuts the brain down at night. Suvorexant works on a different system—the orexin system.